Archive


Category: Atara Biotherapeutics

  • Bayer bails on $670m CAR-T partnership with Atara

    In February, Atara Biotherapeutics paused enrolment into a trial of a CAR-T cell therapy for mesothelioma after a patient death. Now, its partner Bayer has backed out of a partnership covering two mesothelin-directed CAR-Ts signed in 2020. Bayer licensed rights to the two CAR-Ts in a deal worth up to $670 million, including $60 million […]